Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging

Michael S Hofman; Amir Iravani; Tatenda Nzenza; Declan G Murphy

doi:10.1016/j.ucl.2018.03.016

Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging

Urol Clin North Am. 2018 Aug;45(3):503-524. doi: 10.1016/j.ucl.2018.03.016. Epub 2018 Jun 15.

Authors

Michael S Hofman¹, Amir Iravani², Tatenda Nzenza³, Declan G Murphy⁴

Affiliations

¹ Department of Cancer Imaging, Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Victoria 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, 305 Grattan Street, Melbourne, Victoria 3000, Australia.
² Department of Cancer Imaging, Centre for Molecular Imaging, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Victoria 3000, Australia. Electronic address: [email protected].
³ Sir Peter MacCallum Department of Surgical Oncology, University of Melbourne and Austin Hospital, 305 Grattan Street, Melbourne, Victoria 3000, Australia.
⁴ Sir Peter MacCallum Department of Surgical Oncology, University of Melbourne, 305 Grattan Street, Melbourne, Victoria 3000, Australia.

PMID: 30031469
DOI: 10.1016/j.ucl.2018.03.016

Abstract

Radiolabeled prostate-specific membrane antigen PET (PSMA PET) is emerging as an important modality for imaging prostate cancer (PCa). Promising clinical experience has led to increasing number of studies exploring the role of PSMA PET in different aspects of PCa including primary detection, risk stratification, targeted biopsy, initial staging, restaging at biochemical recurrence, biologic characterization, treatment response assessment and prognostication. PSMA PET may prove an important disease biomarker, expand our understanding of the pathogenesis and pave the way for personalized management of PCa.

Keywords: PET; PSMA PET; PSMA PET/CT; Prostate cancer; Prostate-specific membrane antigen.

Publication types

Review

MeSH terms

Antigens, Surface*
Glutamate Carboxypeptidase II*
Humans
Male
Positron Emission Tomography Computed Tomography
Prostatic Neoplasms / diagnostic imaging*
Prostatic Neoplasms / pathology
Prostatic Neoplasms / therapy

Substances

Antigens, Surface
FOLH1 protein, human
Glutamate Carboxypeptidase II